MONTREAL, July 08, 2019 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD, Financial) (“Knight” or the “Company ”), a leading Canadian specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a Normal Course Issuer Bid ("NCIB"). Pursuant to the NCIB, the Company proposes to purchase, from time to time over the next 12 months, if considered advisable, up to 12,053,693 common shares of the Company, being approximately 10% of its public float of 120,536,931 common shares, as of July 2, 2019. As of July 2, 2019, there were a total of 142,868,687 common shares issued and outstanding. Purchases may commence on July 11, 2019 and will conclude on the earlier of the date on which purchases under the bid have been completed and July 10, 2020. The Company may purchase up to a daily maximum of 88,853 Shares (being 25% of the average daily trading volume of 355,415 shares, for the last six calendar months). The common shares may be purchased for cancellation through the facilities of the TSX or through alternative Canadian trading systems at times and in numbers to be determined by the Company. Knight has not purchased any of its common shares in the twelve months preceding this announcement.
Knight Announces Normal Course Issuer Bid
Jul 08, 2019
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers